1
Clinical Trials associated with TBL-0306L / Active, not recruitingPhase 2IIT SURE-02_An Open Label, Single-arm, Phase 2 Study of Perioperative Pembrolizumab Plus Sacituzumab Govitecan, and Bladder-saving Approach, for Patients With Muscle-invasive Bladder Cancer Who Cannot Receive or Refuse Cisplatin-based Chemotherapy
This is a Phase 2, single-center, open-label, non-randomized study in patients with MIBC who cannot receive or refuse to receive cisplatin-based chemotherapy.
Patients will be consecutively enrolled and treated. All patients enrolled who receive at least 1 cycle of study drug will be included in the primary and secondary endpoint analyses.
100 Clinical Results associated with TBL-0306L
100 Translational Medicine associated with TBL-0306L
100 Patents (Medical) associated with TBL-0306L
100 Deals associated with TBL-0306L